GEMTESA® (vibegron) 75 mg tablets

GEMTESA is covered on the TRICARE® Uniform Formulary for ~9 million beneficiaries[1,*]

	GEMTESA
Formulary Tier[2]	**Uniform Formulary – Covered**
Co-Pay[3]	Mail order (Up to a 3-month supply): Active duty $0, Non-active duty $34 Retail (Up to a 1-month supply): Active duty $0, Non-active duty $38 Military treatment facility (up to 30 days): Active duty $0, Non-active $0
Standard Prior Authorization (PA) Criteria† for β3 class[2]	**PA Required:** Tried and failed behavioral interventions Failure of one T1 anticholinergic with exemption for CNS AE or risk of CNS AE

*Coverage status and number of beneficiaries updated October 2022.
†This does not include all PA requirements. Please see the full list of PA criteria in your TRICARE coverage policy.

Personalized Support for the GEMTESA Treatment Journey

Patient CONNECT Support

The Urovant Patient Connect Support program helps patients access GEMTESA with an array of tools and resources.

For more information, please contact your Urovant sales representative or call **1-833-UROVANT**.

INDICATIONS AND USAGE

GEMTESA® is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

GEMTESA is contraindicated in patients with known hypersensitivity to vibegron or any components of the product.

Please see reverse for additional Important Safety Information and accompanying full Prescribing Information.

AE=adverse event, CNS=central nervous system.
Coverage status and number of beneficiaries updated March 2022.

Product images are not actual size.

Pharmacy Information

GEMTESA is available in 30- and 90-day–count bottles

Medication[4]				Wholesaler Item #			
Brand	Strength	Package Configuration	NDC	Amerisource-Bergen	Cardinal Health	McKesson	Other Wholesaler
GEMTESA	75 mg	Bottles of 30	73336-075-30	10254696	5705280	2301489	
GEMTESA	75 mg	Bottles of 90	73336-075-90	10264039	5761408	2381663	

GEMTESA is available through the Department of Defense Pharmaceutical Prime Vendor.

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS

Urinary Retention

Urinary retention has been reported in patients taking GEMTESA. The risk of urinary retention may be increased in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for the treatment of OAB. Monitor patients for signs and symptoms of urinary retention, particularly in patients with bladder outlet obstruction and patients taking muscarinic antagonist medications for the treatment of OAB. Discontinue GEMTESA in patients who develop urinary retention.

ADVERSE REACTIONS

Most common adverse reactions (≥2%) reported with GEMTESA were headache, urinary tract infection, nasopharyngitis, diarrhea, nausea, and upper respiratory tract infection.

Please see full Prescribing Information.

References: 1. MMIT October 2022 Tricare Department of Defense formulary data. **2.** Department of Defense. Department of Defense Pharmacy and Therapeutics Committee recommendations from the August 2022 meeting. **3.** Gemtesa 75 Mg, Tablet. Open Enrollment - Pharmacy Benefit Plans. Published October 24, 2022. Accessed October 24, 2022. https://www.express-scripts.com/frontend/open-enrollment/tricare/fst/#/formularyPricing/results **4.** GEMTESA [Prescribing Information]. Irvine, CA: Urovant Sciences, Inc.

GEMTESA® (vibegron) 75 mg tablets